Disorders characterized by inflammation or scarring in the lungs may be the most complicated area within lung medicine. Not only are the names confusing but they have repeatedly changed over the past 50 years. Furthermore, many of the early studies describing the natural history of one disease or another have turned out to be inaccurate. To make … [Read more...]
Pamrevlumab Ineffective in Treating IPF
In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF. Pamrevlumab entered phase 3 with much anticipation. Phase 2 work suggested that the molecule had a high chance of success. Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function. As a result, Fibrogen … [Read more...]
New Drugs Moving Forward for IPF
BI 1015550 The past few months have brought very exciting news for IPF patients. A novel drug being developed by Boehringer Ingelheim (BI 1015550) showed positive results in a phase 2 study. This new medication blocks the phosphodiesterase 4B receptor. Blockade of this receptor has shown promise in animal models by causing reduced inflammation and … [Read more...]
FAQs: Emphysema, Exercise & Lung Biopsy
Dr. Feldman addresses some common questions below. I have pulmonary fibrosis and emphysema. Why am I so short of breath? Emphysema is often a smoking related lung disease. The air sacs are destroyed and the lung tissue starts to look like Swiss cheese. Pulmonary fibrosis replaces the normal lung tissue with scar formation, especially in the lower … [Read more...]
FAQ’s: Alcohol, Clinical Trials, Pulmonary Function Testing
The past few months have been particularly stressful both in the United States and across the world. As COVID-19 has barreled across the globe, our usual routines have been upended. At PulmonaryFibrosisMD.com we have worked to keep our readers current on major developments. Many of our readers have submitted questions that we will try and address. As always, we greatly … [Read more...]